Bisphosphonates probably overcame borderline of supportive care

Abstract

Zolendronic acid in ABSCG-12 trial demonstrated statisticaly significant improvement of overall survival of patients with early breast cancer.

Keywords

• Bisphosphonates
• metastases
• the standard treatment
• bone destruction
• a complication